S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NYSE:ALTAltimmune Stock Price, Forecast & News

$27.25
+0.67 (+2.52 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$25.55
Now: $27.25
$27.78
50-Day Range
$6.05
MA: $16.55
$33.26
52-Week Range
$1.51
Now: $27.25
$35.10
Volume2.21 million shs
Average Volume3.01 million shs
Market Capitalization$872.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$872.05 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable
$27.25
+0.67 (+2.52 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Altimmune (NYSE:ALT) Frequently Asked Questions

How has Altimmune's stock been impacted by COVID-19 (Coronavirus)?

Altimmune's stock was trading at $3.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALT stock has increased by 754.2% and is now trading at $27.25.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Altimmune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Altimmune
.

When is Altimmune's next earnings date?

Altimmune is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Altimmune
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NYSE:ALT) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.26) EPS for the quarter, beating the Zacks' consensus estimate of ($0.32) by $0.06. The company had revenue of $2.21 million for the quarter, compared to the consensus estimate of $0.50 million.
View Altimmune's earnings history
.

Has Altimmune been receiving favorable news coverage?

Media stories about ALT stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Altimmune earned a news impact score of 1.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Altimmune
.

Who are some of Altimmune's key competitors?

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Crispr Therapeutics (CRSP), Micron Technology (MU), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Novavax (NVAX), Armata Pharmaceuticals (ARMP), Clovis Oncology (CLVS) and Amarin (AMRN).

Who are Altimmune's key executives?

Altimmune's management team includes the following people:
  • Mr. William J. Enright, Pres, CEO & Director (Age 55)
  • Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)
  • Dr. Sybil Tasker, Chief Medical Officer (Age 55)
  • Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer

What is Altimmune's stock symbol?

Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT."

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $27.25.

How big of a company is Altimmune?

Altimmune has a market capitalization of $872.05 million.

What is Altimmune's official website?

The official website for Altimmune is www.altimmune.com.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.